- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSV vaccine MV-012-968 (dosage #1), RSV vaccine MV-012-968 (dosage #2)
- Biological
- Lead sponsor
- Meissa Vaccines, Inc.
- Industry
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Respiratory Syncytial Virus
- Interventions
- mRNA-1345, Placebo
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 0 Years to 40 Years
- Enrollment
- 360 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 22
- States / cities
- Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 19 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- S-337395, Placebo
- Drug
- Lead sponsor
- Shionogi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 192 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 34
- States / cities
- Los Angeles, California • Toluca Lake, California • Coral Gables, Florida + 20 more
- Conditions
- Respiratory Syncytial Virus
- Interventions
- Placebo, mRNA-1345, Afluria® Quadrivalent, mRNA-1273.214
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 3,317 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 62
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Garden Grove, California + 51 more
- Conditions
- Pharmacokinetics, Healthy Volunteers
- Interventions
- BTA-C585 oral capsules, BTA-C585 matching placebo
- Drug
- Lead sponsor
- Biota Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Respiratory Syncytial Virus
- Interventions
- mRNA-1345, Placebo
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 10,994 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 109
- States / cities
- Birmingham, Alabama • Guntersville, Alabama • Huntsville, Alabama + 93 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- GSK3888550A RSV Maternal vaccine formulation 1, GSK3888550A RSV Maternal vaccine formulation 2, GSK3888550A RSV Maternal vaccine formulation 3, Placebo (Normal Saline)
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 502 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 2
- States / cities
- Lenexa, Kansas • Rochester, New York
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSV (GSK3389245A) low dose formulation vaccine, RSV (GSK3389245A) middle dose formulation vaccine, RSV (GSK3389245A) high dose formulation vaccine, Placebo
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Months to 23 Months
- Enrollment
- 107 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 6
- States / cities
- Anaheim, California • Aurora, Colorado • Topeka, Kansas + 3 more
- Conditions
- Respiratory Infections, Acute, Respiratory Syncytial Virus
- Interventions
- RSV challenge material
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 21 Years to 40 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2005
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSVPreF3 formulation 3, RSVPreF3 formulation 2, Boostrix-ex-US, Boostrix-US, Placebo
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 509 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 4
- States / cities
- Miami, Florida • Lenexa, Kansas • Rochester, New York + 1 more
- Conditions
- Respiratory Syncytial Virus
- Interventions
- mRNA-1345, Placebo
- Biological · Drug
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 12 Months to 79 Years
- Enrollment
- 651 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2024
- U.S. locations
- 31
- States / cities
- La Mesa, California • West Hollywood, California • DeLand, Florida + 28 more
- Conditions
- Respiratory Syncytial Virus
- Interventions
- Placebo, mRNA-1345, Fluzone HD
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 1,900 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 34
- States / cities
- Scottsdale, Arizona • Dublin, California • Riverside, California + 29 more
- Conditions
- Influenza A, Influenza Type B, SARS CoV 2 Infection, RSV Infection
- Interventions
- Diagnostic Test for identification of influenzas A, influenzas B, RSV and SARS-CoV-2 infections
- Diagnostic Test
- Lead sponsor
- Baebies, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 2,500 participants
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Raleigh, North Carolina
- Conditions
- Respiratory Syncytial Viruses
- Interventions
- Prior standard of care receipt of Pfizer's ABRYSVO vaccine
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Respiratory Viral Infections, Respiratory Syncytial Virus Infections, Parainfluenza Virus 3, Human
- Interventions
- MEDI-534
- Biological
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 6 Months to 23 Months
- Enrollment
- 49 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2010
- U.S. locations
- 30
- States / cities
- Conway, Arkansas • Little Rock, Arkansas • Aurora, Colorado + 25 more
- Conditions
- Viral Pneumonia
- Interventions
- SNG001, Placebo
- Drug
- Lead sponsor
- Synairgen Research Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 550 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 22
- States / cities
- Sacramento, California • Torrance, California • Naples, Florida + 19 more
- Conditions
- SARS-CoV-2 Infection, Influenza A, Influenza Type B, RSV Infection
- Interventions
- The Applied Biosystems™ TaqPath™ COVID-19, Flu A, Flu B, RSV Select Panel
- Diagnostic Test
- Lead sponsor
- Thermo Fisher Scientific, Inc
- Industry
- Eligibility
- Not listed
- Enrollment
- 1,909 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 17
- States / cities
- San Diego, California • Lake City, Florida • Miami, Florida + 13 more
- Conditions
- Bronchiolitis, Infection, Nitric Oxide
- Interventions
- Not listed
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- Up to 4 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Mineola, New York
- Conditions
- Healthy Participants
- Interventions
- Combination [RSVpreF+BNTb162b2], Bivalent BNT162b2 (original/Omi BA.4/BA.5), RSVpreF, QIV, Normal Saline Placebo
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 1,142 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 37
- States / cities
- Dublin, California • Huntington Beach, California • Lake Forest, California + 26 more
- Conditions
- Acute Respiratory Infection
- Interventions
- Nasal Swab Sample
- Diagnostic Test
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 245 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Guntersville, Alabama • Mesa, Arizona + 30 more
- Conditions
- Pediatric Respiratory Diseases, Asthma, RSV Infection, COVID-19
- Interventions
- RESP™ Biosensor
- Device
- Lead sponsor
- Strados Labs, Inc.
- Industry
- Eligibility
- 4 Years to 17 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Savannah, Georgia
- Conditions
- Respiratory Syncytial Viruses, Respiratory Syncytial Virus Infections
- Interventions
- RSVPreF3 OA investigational vaccine, HZ/su vaccine
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 530 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 11
- States / cities
- Daphne, Alabama • Tempe, Arizona • Corte Madera, California + 8 more
- Conditions
- RSV Infection, Bronchiolitis
- Interventions
- Collection of exhaled breath
- Other
- Lead sponsor
- Winthrop University Hospital
- Other
- Eligibility
- 1 Day to 4 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Mineola, New York
- Conditions
- SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus, Cytomegalovirus
- Interventions
- mRNA-1273, mRNA-1010, mRNA-1345, FLUAD®, mRNA-1647
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 308 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 8
- States / cities
- Hollywood, Florida • Savannah, Georgia • Sioux City, Iowa + 4 more